Literature DB >> 12848761

Cryptococcus neoformans var neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia.

K Assing1, H Birgens, M Arendrup.   

Abstract

Cases of fluconazole-resistant Cryptococcus neoformans have been reported in AIDS patients previously treated with fluconazole. We report a case of fluconazole-resistant cryptococcal meningitis in an HIV-negative patient not previously exposed to fluconazole. The patient experienced a clinical relapse after discontinuation of therapy with amphotericin B and subsequent initiation of fluconazole therapy. In vitro resistance was initially verified by Etest and tablet diffusion and later confirmed by NCCLS broth microdilution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848761     DOI: 10.1046/j.1469-0691.2003.00571.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.

Authors:  Edward Sionov; Yun C Chang; H Martin Garraffo; Michael A Dolan; Mahmoud A Ghannoum; Kyung J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

2.  Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival.

Authors:  Oscar Zaragoza; Cara J Chrisman; Maria Victoria Castelli; Susana Frases; Manuel Cuenca-Estrella; Juan Luis Rodríguez-Tudela; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

3.  Diagnosis and Management of Cryptococcal Relapse.

Authors:  Abdu K Musubire; David R Boulware; David B Meya; Joshua Rhein
Journal:  J AIDS Clin Res       Date:  2013-04-29

4.  Fluconazole induces ROS in Cryptococcus neoformans and contributes to DNA damage in vitro.

Authors:  Congyue Annie Peng; Andrea A E Gaertner; Sarah Ana Henriquez; Diana Fang; Rodney J Colon-Reyes; Julia L Brumaghim; Lukasz Kozubowski
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

5.  Increase of reactive oxygen species contributes to growth inhibition by fluconazole in Cryptococcus neoformans.

Authors:  Nadir Hani Dbouk; Madison Bailey Covington; Kenny Nguyen; Srikripa Chandrasekaran
Journal:  BMC Microbiol       Date:  2019-11-06       Impact factor: 3.605

6.  ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50.

Authors:  Elliot S Gerlach; Sophie Altamirano; J Marina Yoder; Tony S Luggya; Andrew Akampurira; David B Meya; David R Boulware; Joshua Rhein; Kirsten Nielsen
Journal:  Front Cell Infect Microbiol       Date:  2021-06-23       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.